Next Article in Journal
Improving the Endosomal Escape of Cell-Penetrating Peptides and Their Cargos: Strategies and Challenges
Next Article in Special Issue
Mechanistic and Pharmacological Issues of Aspirin as an Anticancer Agent
Previous Article in Journal
Metabolism and Pharmacokinetics of the Anti-Tuberculosis Drug Ethionamide in a Flavin-Containing Monooxygenase Null Mouse
Pharmaceuticals 2012, 5(11), 1160-1176; doi:10.3390/ph5111160
Review

Cyclooxygenase (COX) Inhibitors and the Newborn Kidney

1,2,* , 2,3, 1,2 and 1,2
1 Department of Physiology and Pharmacology, University of Calgary, Alberta, T2N 4N1, Canada 2 Alberta Children's Hospital Research Institute for Child and Maternal Health, University of Calgary, Alberta, T2N 4N1, Canada 3 Department of Pediatrics, University of Calgary, Alberta, T2N 4N1, Canada
* Author to whom correspondence should be addressed.
Received: 17 August 2012 / Revised: 28 September 2012 / Accepted: 15 October 2012 / Published: 25 October 2012
(This article belongs to the Special Issue Cyclooxygenase(COX) Inhibitors)
View Full-Text   |   Download PDF [488 KB, 26 October 2012; original version 25 October 2012]   |   Browse Figures

Abstract

This review summarizes our current understanding of the role of cyclo-oxygenase inhibitors (COXI) in influencing the structural development as well as the function of the developing kidney. COXI administered either during pregnancy or after birth can influence kidney development including nephronogenesis, and can decrease renal perfusion and ultrafiltration potentially leading to acute kidney injury in the newborn period. To date, which COX isoform (COX-1 or COX-2) plays a more important role in during fetal development and influences kidney function early in life is not known, though evidence points to a predominant role for COX-2. Clinical implications of the use of COXI in pregnancy and in the newborn infant are also evaluated herein, with specific reference to the potential effects of COXI on nephronogenesis as well as newborn kidney function.
Keywords: perinatal; prostaglandins; newborn; patent ductus arteriosis; premature labour; indomethacin; COX-1; COX-2; neonate; COX inhibitors perinatal; prostaglandins; newborn; patent ductus arteriosis; premature labour; indomethacin; COX-1; COX-2; neonate; COX inhibitors
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Export to BibTeX |
EndNote


MDPI and ACS Style

Smith, F.G.; Wade, A.W.; Lewis, M.L.; Qi, W. Cyclooxygenase (COX) Inhibitors and the Newborn Kidney. Pharmaceuticals 2012, 5, 1160-1176.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert